{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T02:09:39Z","timestamp":1778206179246,"version":"3.51.4"},"reference-count":146,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K08HL159311"],"award-info":[{"award-number":["K08HL159311"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K23HL169833"],"award-info":[{"award-number":["K23HL169833"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","onlinecjc.ca","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Cardiology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.cjca.2025.12.040","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T08:08:41Z","timestamp":1767773321000},"page":"967-981","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["RNA-Based Therapies for Treating Monogenic Cardiomyopathies"],"prefix":"10.1016","volume":"42","author":[{"given":"Jonathan J.","family":"Edwards","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan B.","family":"Edelson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph W.","family":"Rossano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjca.2025.12.040_bib1","series-title":"Toward precision medicine: building a knowledge network for biomedical research and a new taxonomy of disease","year":"2011"},{"key":"10.1016\/j.cjca.2025.12.040_bib2","doi-asserted-by":"crossref","first-page":"965","DOI":"10.3390\/ijms26030965","article-title":"Optimal chimeric antigen receptor (CAR)-mRNA for transient CAR T cell generation","volume":"26","author":"Kitte","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.cjca.2025.12.040_bib3","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1073\/pnas.75.1.285","article-title":"Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide","volume":"75","author":"Stephenson","year":"1978","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cjca.2025.12.040_bib4","doi-asserted-by":"crossref","first-page":"14514","DOI":"10.1016\/S0021-9258(19)85268-7","article-title":"Evaluation of 2'-modified oligonucleotides containing 2'-deoxy gaps as antisense inhibitors of gene expression","volume":"268","author":"Monia","year":"1993","journal-title":"J Biol Chem"},{"key":"10.1016\/j.cjca.2025.12.040_bib5","first-page":"14","article-title":"Fomivirsen approved for CMV retinitis","volume":"4","author":"Roehr","year":"1998","journal-title":"J Int Assoc Physicians AIDS Care"},{"key":"10.1016\/j.cjca.2025.12.040_bib6","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.3390\/cells13221869","article-title":"Clinical applications of antisense oligonucleotides in cancer: a focus on glioblastoma","volume":"13","author":"Khuu","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.cjca.2025.12.040_bib7","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2025.12.040_bib8","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2025.12.040_bib9","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/nbt.3589","article-title":"Translation efficiency of mRNAs is increased by antisense oligonucleotides targeting upstream open reading frames","volume":"34","author":"Liang","year":"2016","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.cjca.2025.12.040_bib10","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/35888","article-title":"Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans","volume":"391","author":"Fire","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.cjca.2025.12.040_bib11","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/35078107","article-title":"Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells","volume":"411","author":"Elbashir","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.cjca.2025.12.040_bib12","first-page":"1397","article-title":"Distinct roles for RDE-1 and RDE-4 during RNA interference in Caenorhabditis elegans","volume":"7","author":"Parrish","year":"2001","journal-title":"RNA"},{"key":"10.1016\/j.cjca.2025.12.040_bib13","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.3390\/cells8091103","article-title":"Understanding the modus operandi of microRNA regulatory clusters","volume":"8","author":"Oliveira","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.cjca.2025.12.040_bib14","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1073\/pnas.032652399","article-title":"Stable suppression of gene expression by RNAi in mammalian cells","volume":"99","author":"Paddison","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cjca.2025.12.040_bib15","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2025.12.040_bib16","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2025.12.040_bib17","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0960-9822(02)00482-7","article-title":"Codon usage limitation in the expression of HIV-1 envelope glycoprotein","volume":"6","author":"Haas","year":"1996","journal-title":"Curr Biol"},{"key":"10.1016\/j.cjca.2025.12.040_bib18","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1182\/blood-2006-04-015024","article-title":"Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells","volume":"108","author":"Holtkamp","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.cjca.2025.12.040_bib19","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","article-title":"Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA","volume":"23","author":"Karik\u00f3","year":"2005","journal-title":"Immunity"},{"key":"10.1016\/j.cjca.2025.12.040_bib20","first-page":"1486","article-title":"Synthesis and properties of mRNAs containing the novel \u201canti-reverse\u201d cap analogs 7-methyl(3'-O-methyl)GpppG and 7-methyl (3'-deoxy)GpppG","volume":"7","author":"Stepinski","year":"2001","journal-title":"RNA"},{"key":"10.1016\/j.cjca.2025.12.040_bib21","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1096\/fasebj.7.1.7678559","article-title":"Mis-splicing yields circular RNA molecules","volume":"7","author":"Cocquerelle","year":"1993","journal-title":"FASEB J"},{"key":"10.1016\/j.cjca.2025.12.040_bib22","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1056\/NEJMoa2504747","article-title":"Patient-specific in vivo gene editing to treat a rare genetic disease","volume":"392","author":"Musunuru","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2025.12.040_bib23","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.cell.2010.06.040","article-title":"A large intergenic noncoding RNA induced by p53 mediates global gene repression in the p53 response","volume":"142","author":"Huarte","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.cjca.2025.12.040_bib24","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.molcel.2013.08.027","article-title":"The imprinted H19 lncRNA antagonizes let-7 microRNAs","volume":"52","author":"Kallen","year":"2013","journal-title":"Mol Cell"},{"key":"10.1016\/j.cjca.2025.12.040_bib25","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.molcel.2010.08.011","article-title":"The nuclear-retained noncoding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor phosphorylation","volume":"39","author":"Tripathi","year":"2010","journal-title":"Mol Cell"},{"key":"10.1016\/j.cjca.2025.12.040_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174719","article-title":"Long non-coding RNA MALAT1 modulates myocardial ischemia-reperfusion injury through the PI3K\/Akt\/eNOS pathway by sponging miRNA-133a-3p to target IGF1R expression","volume":"916","author":"Liu","year":"2022","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.cjca.2025.12.040_bib27","first-page":"1367","article-title":"LncRNA NEAT1 promotes cardiac hypertrophy through microRNA-19a-3p\/SMYD2 axis","volume":"24","author":"Sun","year":"2020","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.cjca.2025.12.040_bib28","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nrd1955","article-title":"Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease","volume":"5","author":"Ng","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.cjca.2025.12.040_bib29","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1056\/NEJMoa042760","article-title":"Pegaptanib for neovascular age-related macular degeneration","volume":"351","author":"Gragoudas","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2025.12.040_bib30","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.bioeng.2007.06.001","article-title":"SELEX--a (r)evolutionary method to generate high-affinity nucleic acid ligands","volume":"24","author":"Stoltenburg","year":"2007","journal-title":"Biomol Eng"},{"key":"10.1016\/j.cjca.2025.12.040_bib31","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1126\/science.2200121","article-title":"Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase","volume":"249","author":"Tuerk","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.cjca.2025.12.040_bib32","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1111\/j.1538-7836.2005.01328.x","article-title":"Spatial and temporal dynamics of the endothelium","volume":"3","author":"Aird","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.cjca.2025.12.040_bib33","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.immuni.2012.12.001","article-title":"Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis","volume":"38","author":"Yona","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.cjca.2025.12.040_bib34","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1152\/ajplegacy.1958.193.1.161","article-title":"Regional blood flow by fractional distribution of indicators","volume":"193","author":"Sapirstein","year":"1958","journal-title":"Am J Physiol"},{"key":"10.1016\/j.cjca.2025.12.040_bib35","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.3390\/ijms22052382","article-title":"Baack ML Mitochondrial transfer improves cardiomyocyte bioenergetics and viability in male rats exposed to pregestational diabetes","volume":"22","author":"Louwagie","year":"2027","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.cjca.2025.12.040_bib36","doi-asserted-by":"crossref","first-page":"570","DOI":"10.3181\/00379727-84-20714","article-title":"Isolation of a cytopathogenic agent from human adenoids undergoing spontaneous degeneration in tissue culture","volume":"84","author":"Rowe","year":"1953","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1016\/j.cjca.2025.12.040_bib37","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/371802a0","article-title":"Inefficient gene transfer by adenovirus vector to cystic fibrosis airway epithelia of mice and humans","volume":"371","author":"Grubb","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.cjca.2025.12.040_bib38","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ymgme.2003.08.016","article-title":"Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer","volume":"80","author":"Raper","year":"2003","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.cjca.2025.12.040_bib39","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abd3438","article-title":"Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses","volume":"13","author":"Chan","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.cjca.2025.12.040_bib40","doi-asserted-by":"crossref","first-page":"4919","DOI":"10.1016\/j.cell.2021.08.028","article-title":"Directed evolution of a family of AAV capsid variants enabling potent muscle-directed gene delivery across species","volume":"184","author":"Tabebordbar","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.cjca.2025.12.040_bib41","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S0140-6736(09)61836-5","article-title":"Age-dependent effects of RPE65 gene therapy for Leber\u2019s congenital amaurosis: a phase 1 dose-escalation trial","volume":"374","author":"Maguire","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2025.12.040_bib42","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2025.12.040_bib43","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","article-title":"Adenovirus-associated virus vector-mediated gene transfer in hemophilia B","volume":"365","author":"Nathwani","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2025.12.040_bib44","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","article-title":"Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial","volume":"390","author":"Russell","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2025.12.040_bib45","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/S0140-6736(16)00082-9","article-title":"Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial","volume":"387","author":"Greenberg","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2025.12.040_bib46","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1056\/NEJMoa2412392","article-title":"Phase 1 study of AAV9.LAMP2B gene therapy in Danon disease","volume":"392","author":"Greenberg","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2025.12.040_bib47","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(97)00128-2","article-title":"Interactions of liposomes and lipid-based carrier systems with blood proteins: relation to clearance behaviour in vivo","volume":"32","author":"Cullis","year":"1998","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.cjca.2025.12.040_bib48","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nbt.1602","article-title":"Rational design of cationic lipids for siRNA delivery","volume":"28","author":"Semple","year":"2010","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.cjca.2025.12.040_bib49","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3390\/vaccines9010065","article-title":"Nanomaterial delivery systems for mRNA vaccines","volume":"9","author":"Buschmann","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.cjca.2025.12.040_bib50","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/j.ymthe.2017.03.013","article-title":"Lipid nanoparticle systems for enabling gene therapies","volume":"25","author":"Cullis","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.cjca.2025.12.040_bib51","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/mt.2010.85","article-title":"Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms","volume":"18","author":"Akinc","year":"2010","journal-title":"Mol Ther"},{"key":"10.1016\/j.cjca.2025.12.040_bib52","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2409266122","article-title":"Systemic delivery of biotherapeutic RNA to the myocardium transiently modulates cardiac contractility in vivo","volume":"122","author":"Shuvaev","year":"2025","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cjca.2025.12.040_bib53","doi-asserted-by":"crossref","first-page":"16958","DOI":"10.1021\/ja505986a","article-title":"Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing","volume":"136","author":"Nair","year":"2014","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.cjca.2025.12.040_bib54","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s40265-020-01269-0","article-title":"Givosiran: first approval","volume":"80","author":"Scott","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.cjca.2025.12.040_bib55","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/nature03121","article-title":"Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs","volume":"432","author":"Soutschek","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.cjca.2025.12.040_bib56","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkaf270","article-title":"Conjugation to a transferrin receptor 1-binding bicycle peptide enhances ASO and siRNA potency in skeletal and cardiac muscles","volume":"53","author":"\u00d8stergaard","year":"2025","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.cjca.2025.12.040_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.crtox.2024.100182","article-title":"Comprehensive review of adverse reactions and toxicology in ASO-based therapies for Duchenne muscular dystrophy: from FDA-approved drugs to peptide-conjugated ASO","volume":"7","author":"Sabrina Haque","year":"2024","journal-title":"Curr Res Toxicol"},{"key":"10.1016\/j.cjca.2025.12.040_bib58","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.ebiom.2019.06.036","article-title":"Peptide-conjugate antisense based splice-correction for Duchenne muscular dystrophy and other neuromuscular diseases","volume":"45","author":"Tsoumpra","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.cjca.2025.12.040_bib59","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nature15756","article-title":"Tumour exosome integrins determine organotropic metastasis","volume":"527","author":"Hoshino","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.cjca.2025.12.040_bib60","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41556-018-0250-9","article-title":"Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication","volume":"21","author":"Mathieu","year":"2019","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.cjca.2025.12.040_bib61","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.healun.2023.08.011","article-title":"Pleiotropic effects of extracellular vesicles from induced pluripotent stem cell-derived cardiomyocytes on ischemic cardiomyopathy: a preclinical study","volume":"43","author":"Tominaga","year":"2024","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.cjca.2025.12.040_bib62","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1016\/j.jacc.2016.02.081","article-title":"Dystrophin-deficient cardiomyopathy","volume":"67","author":"Kamdar","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2025.12.040_bib63","doi-asserted-by":"crossref","first-page":"8823","DOI":"10.3390\/molecules20058823","article-title":"Current understanding of molecular pathology and treatment of cardiomyopathy in Duchenne muscular dystrophy","volume":"20","author":"van Westering","year":"2015","journal-title":"Molecules"},{"key":"10.1016\/j.cjca.2025.12.040_bib64","doi-asserted-by":"crossref","first-page":"5447","DOI":"10.1007\/s00018-021-03862-2","article-title":"The multifaceted view of heart problem in Duchenne muscular dystrophy","volume":"78","author":"Florczyk-Soluch","year":"2021","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.cjca.2025.12.040_bib65","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.3390\/cells13141168","article-title":"Cardiomyopathy in Duchenne muscular dystrophy and the potential for mitochondrial therapeutics to improve treatment response","volume":"13","author":"Gandhi","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.cjca.2025.12.040_bib66","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1056\/NEJMra0907180","article-title":"New therapeutic approaches to mendelian disorders","volume":"363","author":"Dietz","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2025.12.040_bib67","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1161\/CIR.0000000000001151","article-title":"Treatment strategies for cardiomyopathy in children: a scientific statement from the American Heart Association","volume":"148","author":"Bogle","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2025.12.040_bib68","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.3390\/biom13091319","article-title":"Advances in dystrophinopathy diagnosis and therapy","volume":"13","author":"Saad","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.cjca.2025.12.040_bib69","doi-asserted-by":"crossref","first-page":"989","DOI":"10.3233\/JND-210643","article-title":"Open-label evaluation of eteplirsen in patients with Duchenne muscular dystrophy amenable to exon 51 skipping: PROMOVI trial","volume":"8","author":"McDonald","year":"2021","journal-title":"J Neuromuscul Dis"},{"key":"10.1016\/j.cjca.2025.12.040_bib70","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1001\/jamaneurol.2020.1264","article-title":"Safety, tolerability, and efficacy of viltolarsen in boys with Duchenne muscular dystrophy amenable to exon 53 skipping: a phase 2 randomized clinical trial","volume":"77","author":"Clemens","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.cjca.2025.12.040_bib71","doi-asserted-by":"crossref","first-page":"e2270","DOI":"10.1212\/WNL.0000000000009233","article-title":"Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy [erratum in: 2023;100:936]","volume":"94","author":"Frank","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.cjca.2025.12.040_bib72","doi-asserted-by":"crossref","first-page":"912","DOI":"10.3390\/biomedicines12040912","article-title":"Casimersen (AMONDYS 45): an antisense oligonucleotide for Duchenne muscular dystrophy","volume":"12","author":"Assefa","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.cjca.2025.12.040_bib73","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1038\/s41591-025-03750-3","article-title":"AAV mini-dystrophin gene therapy for Duchenne muscular dystrophy: a phase 1b trial","volume":"31","author":"Butterfield","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.cjca.2025.12.040_bib74","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.165869","article-title":"Potential limitations of microdystrophin gene therapy for Duchenne muscular dystrophy","volume":"9","author":"Hart","year":"2024","journal-title":"JCI Insight"},{"key":"10.1016\/j.cjca.2025.12.040_bib75","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1001\/jamaneurol.2020.1484","article-title":"Assessment of systemic delivery of rAAVrh74.MHCK7.micro-dystrophin in children with Duchenne muscular dystrophy: a nonrandomized controlled trial","volume":"77","author":"Mendell","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.cjca.2025.12.040_bib76","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41586-024-08539-x","article-title":"Transcriptional adaptation upregulates utrophin in Duchenne muscular dystrophy","volume":"639","author":"Falcucci","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.cjca.2025.12.040_bib77","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.medj.2023.02.005","article-title":"Unusually severe muscular dystrophy upon in-frame deletion of the dystrophin rod domain and lack of compensation by membrane-localized utrophin","volume":"4","author":"Gorokhova","year":"2023","journal-title":"Med"},{"key":"10.1016\/j.cjca.2025.12.040_bib78","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0092-8674(00)80532-2","article-title":"Utrophin-dystrophin-deficient mice as a model for Duchenne muscular dystrophy","volume":"90","author":"Deconinck","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.cjca.2025.12.040_bib79","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1038\/s41467-025-57831-5","article-title":"Activation of endogenous full-length utrophin by MyoAAV-UA as a therapeutic approach for Duchenne muscular dystrophy","volume":"16","author":"Wu","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.cjca.2025.12.040_bib80","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1038\/s41591-019-0594-0","article-title":"Non-immunogenic utrophin gene therapy for the treatment of muscular dystrophy animal models","volume":"25","author":"Song","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.cjca.2025.12.040_bib81","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.3389\/fphys.2019.01436","article-title":"The giant protein titin\u2019s role in cardiomyopathy: genetic, transcriptional, and post-translational modifications of TTN and their contribution to cardiac disease","volume":"10","author":"Tharp","year":"2019","journal-title":"Front Physiol"},{"key":"10.1016\/j.cjca.2025.12.040_bib82","doi-asserted-by":"crossref","first-page":"4093","DOI":"10.1038\/s41598-019-39911-x","article-title":"Relevance of titin missense and non-frameshifting insertions\/deletions variants in dilated cardiomyopathy","volume":"9","author":"Akinrinade","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.cjca.2025.12.040_bib83","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1056\/NEJMoa1110186","article-title":"Truncations of titin causing dilated cardiomyopathy","volume":"366","author":"Herman","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2025.12.040_bib84","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1161\/CIRCULATIONAHA.119.039573","article-title":"Genomics-first evaluation of heart disease associated with titin-truncating variants [erratum in: 2019;140:e727]","volume":"140","author":"Haggerty","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2025.12.040_bib85","doi-asserted-by":"crossref","DOI":"10.1172\/JCI170196","article-title":"Truncated titin protein in dilated cardiomyopathy incorporates into the sarcomere and transmits force","volume":"134","author":"McAfee","year":"2024","journal-title":"J Clin Invest"},{"key":"10.1016\/j.cjca.2025.12.040_bib86","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abd7287","article-title":"Truncated titin proteins in dilated cardiomyopathy","volume":"13","author":"McAfee","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.cjca.2025.12.040_bib87","doi-asserted-by":"crossref","first-page":"562","DOI":"10.15252\/emmm.201505047","article-title":"Antisense-mediated exon skipping: a therapeutic strategy for titin-based dilated cardiomyopathy","volume":"7","author":"Gramlich","year":"2015","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.cjca.2025.12.040_bib88","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.yjmcc.2019.04.014","article-title":"The assembly and evaluation of antisense oligonucleotides applied in exon skipping for titin-based mutations in dilated cardiomyopathy","volume":"131","author":"Hahn","year":"2019","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.cjca.2025.12.040_bib89","doi-asserted-by":"crossref","first-page":"e1239","DOI":"10.1161\/CIR.0000000000001250","article-title":"2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"149","author":"Ommen","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2025.12.040_bib90","doi-asserted-by":"crossref","DOI":"10.1016\/j.ceca.2023.102822","article-title":"Enhanced myofilament calcium sensitivity aggravates abnormal calcium handling and diastolic dysfunction in patient-specific induced pluripotent stem cell-derived cardiomyocytes with MYH7 mutation","volume":"117","author":"Guo","year":"2024","journal-title":"Cell Calcium"},{"key":"10.1016\/j.cjca.2025.12.040_bib91","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1161\/CIRCRESAHA.121.318346","article-title":"Molecular genetic basis of hypertrophic cardiomyopathy","volume":"128","author":"Marian","year":"2021","journal-title":"Circ Res"},{"key":"10.1016\/j.cjca.2025.12.040_bib92","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1161\/CIRCRESAHA.117.311059","article-title":"Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy","volume":"121","author":"Marian","year":"2017","journal-title":"Circ Res"},{"key":"10.1016\/j.cjca.2025.12.040_bib93","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/j.omtn.2020.01.012","article-title":"Allele-selective knockdown of MYH7 using antisense oligonucleotides","volume":"19","author":"Anderson","year":"2020","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.cjca.2025.12.040_bib94","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1126\/science.1236921","article-title":"Allele-specific silencing of mutant Myh6 transcripts in mice suppresses hypertrophic cardiomyopathy","volume":"342","author":"Jiang","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.cjca.2025.12.040_bib95","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/s41591-022-02190-7","article-title":"Efficient in vivo genome editing prevents hypertrophic cardiomyopathy in mice","volume":"29","author":"Reichart","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.cjca.2025.12.040_bib96","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1161\/CIRCULATIONAHA.123.067890","article-title":"Allele-specific suppression of variant MHC with high-precision RNA nuclease CRISPR-Cas13d prevents hypertrophic cardiomyopathy","volume":"150","author":"Yang","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2025.12.040_bib97","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/ng.309","article-title":"A common MYBPC3 (cardiac myosin binding protein C) variant associated with cardiomyopathies in South Asia","volume":"41","author":"Dhandapany","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.cjca.2025.12.040_bib98","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.133782","article-title":"Effects of MYBPC3 loss-of-function mutations preceding hypertrophic cardiomyopathy","volume":"5","author":"Helms","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.cjca.2025.12.040_bib99","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2023.105511","article-title":"Missense mutations in the central domains of cardiac myosin binding protein-C and their potential contribution to hypertrophic cardiomyopathy","volume":"300","author":"Pearce","year":"2024","journal-title":"J Biol Chem"},{"key":"10.1016\/j.cjca.2025.12.040_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.100854","article-title":"Protein haploinsufficiency drivers identify MYBPC3 variants that cause hypertrophic cardiomyopathy","volume":"297","author":"Suay-Corredera","year":"2021","journal-title":"J Biol Chem"},{"key":"10.1016\/j.cjca.2025.12.040_bib101","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aat1199","article-title":"Hypertrophic cardiomyopathy mutations in MYBPC3 dysregulate myosin","volume":"11","author":"Toepfer","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.cjca.2025.12.040_bib102","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1038\/s41467-025-57481-7","article-title":"AAV9-mediated MYBPC3 gene therapy with optimized expression cassette enhances cardiac function and survival in MYBPC3 cardiomyopathy models","volume":"16","author":"Greer-Short","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.cjca.2025.12.040_bib104","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/emmm.201202168","article-title":"Rescue of cardiomyopathy through U7snRNA-mediated exon skipping in Mybpc3-targeted knock-in mice","volume":"5","author":"Gedicke-Hornung","year":"2013","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.cjca.2025.12.040_bib105","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2013.31","article-title":"Repair of Mybpc3 mRNA by 5'-trans-splicing in a mouse model of hypertrophic cardiomyopathy","volume":"2","author":"Mearini","year":"2013","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.cjca.2025.12.040_bib106","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.omtn.2017.05.008","article-title":"Evaluation of MYBPC3 trans-splicing and gene replacement as therapeutic options in human iPSC-derived cardiomyocytes","volume":"7","author":"Prondzynski","year":"2017","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.cjca.2025.12.040_bib107","doi-asserted-by":"crossref","first-page":"11115","DOI":"10.1073\/pnas.1710354114","article-title":"Molecular mechanisms and structural features of cardiomyopathy-causing troponin T mutants in the tropomyosin overlap region","volume":"114","author":"Gangadharan","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cjca.2025.12.040_bib108","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.005407","article-title":"Pathogenesis of hypertrophic cardiomyopathy is mutation rather than disease specific: a comparison of the cardiac troponin T E163R and R92Q mouse models","volume":"6","author":"Ferrantini","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cjca.2025.12.040_bib109","doi-asserted-by":"crossref","first-page":"4677","DOI":"10.1113\/JP274145","article-title":"Genotype-specific pathogenic effects in human dilated cardiomyopathy","volume":"595","author":"Bollen","year":"2017","journal-title":"J Physiol"},{"key":"10.1016\/j.cjca.2025.12.040_bib110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0002642","article-title":"The role of cardiac troponin T quantity and function in cardiac development and dilated cardiomyopathy","volume":"3","author":"Ahmad","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.cjca.2025.12.040_bib111","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1177\/15353702211072453","article-title":"Allele-specific silencing by RNAi of R92Q and R173W mutations in cardiac troponin T","volume":"247","author":"Migliore","year":"2022","journal-title":"Exp Biol Med (Maywood)"},{"key":"10.1016\/j.cjca.2025.12.040_bib112","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13578-023-01143-y","article-title":"Cas13b-mediated RNA targeted therapy alleviates genetic dilated cardiomyopathy in mice","volume":"14","author":"Li","year":"2024","journal-title":"Cell Biosci"},{"key":"10.1016\/j.cjca.2025.12.040_bib113","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.864191","article-title":"Post-translational modification of lamins: mechanisms and functions","volume":"10","author":"Zheng","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.cjca.2025.12.040_bib114","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.stem.2020.12.016","article-title":"Pathogenic LMNA variants disrupt cardiac lamina-chromatin interactions and de-repress alternative fate genes","volume":"28","author":"Shah","year":"2021","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.cjca.2025.12.040_bib115","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1161\/CIRCRESAHA.118.314238","article-title":"DNA damage response\/TP53 pathway is activated and contributes to the pathogenesis of dilated cardiomyopathy associated with LMNA (Lamin A\/C) mutations","volume":"124","author":"Chen","year":"2019","journal-title":"Circ Res"},{"key":"10.1016\/j.cjca.2025.12.040_bib116","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adh0798","article-title":"Perinuclear damage from nuclear envelope deterioration elicits stress responses that contribute to LMNA cardiomyopathy","volume":"10","author":"Sikder","year":"2024","journal-title":"Sci Adv"},{"key":"10.1016\/j.cjca.2025.12.040_bib117","doi-asserted-by":"crossref","first-page":"7000","DOI":"10.1038\/s41467-024-51318-5","article-title":"Lamin A\/C deficiency-mediated ROS elevation contributes to pathogenic phenotypes of dilated cardiomyopathy in iPSC model","volume":"15","author":"Qiu","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.cjca.2025.12.040_bib118","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1186\/s12967-023-04542-4","article-title":"Systematic in vivo candidate evaluation uncovers therapeutic targets for LMNA dilated cardiomyopathy and risk of lamin A toxicity","volume":"21","author":"Tan","year":"2023","journal-title":"J Transl Med"},{"key":"10.1016\/j.cjca.2025.12.040_bib119","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.005677","article-title":"Modeling treatment response for lamin A\/C related dilated cardiomyopathy in human induced pluripotent stem cells","volume":"6","author":"Lee","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cjca.2025.12.040_bib120","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1056\/NEJMicm2119255","article-title":"Arrhythmogenic right ventricular cardiomyopathy","volume":"387","author":"McCullough","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2025.12.040_bib121","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1038\/s41436-021-01233-7","article-title":"The genetic architecture of Plakophilin 2 cardiomyopathy","volume":"23","author":"Dries","year":"2021","journal-title":"Genet Med"},{"key":"10.1016\/j.cjca.2025.12.040_bib122","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1161\/CIRCULATIONAHA.122.060454","article-title":"Loss of nuclear envelope integrity and increased oxidant production cause DNA damage in adult hearts deficient in PKP2: a molecular substrate of ARVC","volume":"146","author":"P\u00e9rez-Hern\u00e1ndez","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2025.12.040_bib123","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGEN.123.004305","article-title":"AAV-mediated delivery of plakophilin-2a arrests progression of arrhythmogenic right ventricular cardiomyopathy in murine hearts: preclinical evidence supporting gene therapy in humans","volume":"17","author":"van Opbergen","year":"2024","journal-title":"Circ Genom Precis Med"},{"key":"10.1016\/j.cjca.2025.12.040_bib124","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.stemcr.2021.12.016","article-title":"Modeling reduced contractility and impaired desmosome assembly due to plakophilin-2 deficiency using isogenic iPS cell-derived cardiomyocytes","volume":"17","author":"Inoue","year":"2022","journal-title":"Stem Cell Reports"},{"key":"10.1016\/j.cjca.2025.12.040_bib125","doi-asserted-by":"crossref","first-page":"6947","DOI":"10.3390\/ijms23136947","article-title":"Aberrant PLN-R14del protein interactions intensify SERCA2a inhibition, driving impaired Ca(2+) handling and arrhythmogenesis","volume":"23","author":"Vafiadaki","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.cjca.2025.12.040_bib126","doi-asserted-by":"crossref","first-page":"16521","DOI":"10.1074\/jbc.M112.360859","article-title":"Hydrophobic imbalance in the cytoplasmic domain of phospholamban is a determinant for lethal dilated cardiomyopathy","volume":"287","author":"Ceholski","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1016\/j.cjca.2025.12.040_bib127","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.3390\/ijms23052427","article-title":"Antisense therapy attenuates phospholamban p.(Arg14del) cardiomyopathy in mice and reverses protein aggregation","volume":"23","author":"Eijgenraam","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.cjca.2025.12.040_bib128","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.1038\/s41467-021-25439-0","article-title":"Phospholamban antisense oligonucleotides improve cardiac function in murine cardiomyopathy","volume":"12","author":"Grote Beverborg","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.cjca.2025.12.040_bib129","article-title":"A novel artificial microRNA expressing AAV vector for phospholamban silencing in cardiomyocytes improves Ca2+ uptake into the sarcoplasmic reticulum","volume":"9","author":"Gr\u00f6\u03b2l","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.cjca.2025.12.040_bib130","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1161\/CIRCULATIONAHA.108.783852","article-title":"Long-term cardiac-targeted RNA interference for the treatment of heart failure restores cardiac function and reduces pathological hypertrophy","volume":"119","author":"Suckau","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2025.12.040_bib131","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.yjmcc.2014.09.006","article-title":"A cell-penetrating phospholamban-specific RNA aptamer enhances Ca2+ transients and contractile function in cardiomyocytes","volume":"76","author":"Sakai","year":"2014","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.cjca.2025.12.040_bib132","doi-asserted-by":"crossref","DOI":"10.1038\/srep13000","article-title":"Rheostatic regulation of the SERCA\/phospholamban membrane protein complex using non-coding RNA and single-stranded DNA oligonucleotides","volume":"5","author":"Soller","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.cjca.2025.12.040_bib133","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2024.1433721","article-title":"Editorial: proteostasis in cardiac health and disease","volume":"11","author":"B\u00fchringer","year":"2024","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.cjca.2025.12.040_bib134","first-page":"406","article-title":"Altered proteasome function in right ventricular hypertrophy","volume":"116","author":"Heitmeier","year":"2020","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.cjca.2025.12.040_bib135","doi-asserted-by":"crossref","first-page":"H551","DOI":"10.1152\/ajpheart.00771.2012","article-title":"Altered ubiquitin-proteasome signaling in right ventricular hypertrophy and failure","volume":"305","author":"Rajagopalan","year":"2013","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.cjca.2025.12.040_bib136","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.027373","article-title":"Genetics of BAG3: a paradigm for developing precision therapies for dilated cardiomyopathies","volume":"11","author":"Qu","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cjca.2025.12.040_bib137","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.1038\/s41467-021-23858-7","article-title":"Overexpression of human BAG3(P209L) in mice causes restrictive cardiomyopathy","volume":"12","author":"Kimura","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.cjca.2025.12.040_bib138","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1159\/000445641","article-title":"Overexpression of BAG3 attenuates hypoxia-induced cardiomyocyte apoptosis by inducing autophagy","volume":"39","author":"Zhang","year":"2016","journal-title":"Cell Physiol Biochem"},{"key":"10.1016\/j.cjca.2025.12.040_bib139","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.jacbts.2016.08.008","article-title":"Adeno-associated virus serotype 9 - driven expression of BAG3 improves left ventricular function in murine hearts with left ventricular dysfunction secondary to a myocardial infarction","volume":"1","author":"Knezevic","year":"2016","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.cjca.2025.12.040_bib140","article-title":"Future of genetic therapies for rare genetic diseases: what to expect for the next 15 years?","volume":"3","author":"Braga","year":"2022","journal-title":"Ther Adv Rare Dis"},{"key":"10.1016\/j.cjca.2025.12.040_bib141","article-title":"The past, the present, and the future of genomic therapies in cardiovascular disease","volume":"13","author":"McNally","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cjca.2025.12.040_bib142","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.jacc.2004.05.049","article-title":"Altered myocardial Ca2+ cycling after left ventricular assist device support in the failing human heart","volume":"44","author":"Chaudhary","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2025.12.040_bib143","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/ncpcardio1301","article-title":"The cardiac sarcoplasmic\/endoplasmic reticulum calcium ATPase: a potent target for cardiovascular diseases","volume":"5","author":"Kawase","year":"2008","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"10.1016\/j.cjca.2025.12.040_bib144","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1073\/pnas.97.2.793","article-title":"Adenoviral gene transfer of SERCA2a improves left-ventricular function in aortic-banded rats in transition to heart failure","volume":"97","author":"Miyamoto","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cjca.2025.12.040_bib145","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.cardfail.2009.01.013","article-title":"Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID trial), a first-in-human phase 1\/2 clinical trial","volume":"15","author":"Jaski","year":"2009","journal-title":"J Card Fail"},{"key":"10.1016\/j.cjca.2025.12.040_bib146","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1161\/CIRCULATIONAHA.111.022889","article-title":"Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure","volume":"124","author":"Jessup","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2025.12.040_bib147","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s10974-024-09688-2","article-title":"Progress and prospects in antisense oligonucleotide-mediated exon skipping therapies for Duchenne muscular dystrophy","volume":"46","author":"Chwalenia","year":"2025","journal-title":"J Muscle Res Cell Motil"}],"container-title":["Canadian Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X25016083?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X25016083?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T01:12:34Z","timestamp":1778202754000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0828282X25016083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":146,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0828282X25016083"],"URL":"https:\/\/doi.org\/10.1016\/j.cjca.2025.12.040","relation":{},"ISSN":["0828-282X"],"issn-type":[{"value":"0828-282X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"RNA-Based Therapies for Treating Monogenic Cardiomyopathies","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjca.2025.12.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}